RET fusion genes in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4439-4441

  Chao, Bo H ^a,b   Briesewitz, Roger ^b   Villalona Calero, Miguel A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALK PROTEIN; CRIZOTINIB; KIF5B PROTEIN; PROTEIN; PROTEIN RET; ROS1 PROTEIN; UNCLASSIFIED DRUG; VANDETANIB;

CANCER PATIENT; FUSION GENE; GENE IDENTIFICATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS C-RET;

EID: 84870758016     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8240     Document Type: Review

References (38)

1. Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007 (Pubitemid 46425867)
2. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
3. le Coutre P, Ottmann OG, Giles F, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834-1839, 2008 (Pubitemid 351451490)
4. Lee YJ, Kim JH, Kim SK, et al: Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer 72:9-15, 2011
5. Subramanian J, Govindan R: Lung cancer in "Never-smokers": A unique entity. Oncology (Williston Park) 24:29-35, 2010
6. Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers: A different disease. Nat Rev Cancer 7:778-790, 2007 (Pubitemid 47463669)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
8. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
9. Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42:581-588, 1985 (Pubitemid 16091150)
10. Ju YS, Lee WC, Shin JY, et al: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22:436-445, 2012
11. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
12. Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-377, 2012
13. Li F, Feng Y, Fang R, et al: Identification of RET gene fusion by exon array analyses in "pannegative"lung cancer from never smokers. Cell Res 22:928-931, 2012
14. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
15. Su AI, Cooke MP, Ching KA, et al: Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99:4465-4470, 2002 (Pubitemid 34286008)
16. Wang R, Hu H, Pan Y, et al: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30:4352-4359, 2012
17. Pao W, Hutchinson KE: Chipping away at the lung cancer genome. Nat Med 18:349-351, 2012
18. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284, 1994 (Pubitemid 24107549)
19. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007 (Pubitemid 350235027)
20. Zbuk KM, Eng C: Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7:35-45, 2007 (Pubitemid 46020845)
21. Jing S, Wen D, Yu Y, et al: GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124, 1996 (Pubitemid 26231176)
22. Grieco M, Santoro M, Berlingieri MT, et al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563, 1990
23. Santoro M, Dathan NA, Berlingieri MT, et al: Molecular characterization of RET/PTC3: A novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509-516, 1994 (Pubitemid 24041530)
24. Score J, Curtis C, Waghorn K, et al: Identification of a novel imatinib responsive KIF5BPDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20:827-832, 2006
25. Takeuchi K, Choi YL, Togashi Y, et al: KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143-3149, 2009
26. Alberti L, Carniti C, Miranda C, et al: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195:168-186, 2003 (Pubitemid 36384291)
27. Phay JE, Shah MH: Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16:5936-5941, 2010
28. Faivre S, Djelloul S, Raymond E: New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33:407-420, 2006 (Pubitemid 44142738)
29. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
30. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
31. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 30:134-141, 2012
32. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
33. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
34. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
35. Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318, 2009
36. Lee JS, Hirsh V, Park K, et al: Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30:1114-1121, 2012
37. Paz-Ares LG, Biesma B, Heigener D, et al: Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084-3092, 2012
38. Scagliotti GV, Krzakowski M, Szczesna A, et al: Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial. J Clin Oncol 30:2070-2078, 2012